KOSDAQBiotech & Pharma082800

Vivozon Pharmaceutical

₩2,780 0.00%2026-11-18 close
Market Cap
₩168.8B
Turnover
₩300M
Volume
100K
Shares out.
60.7M
PER
—
PBR
1.9×
EPS
-₩417
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Anaprazole Uptake and Narrowing Losses, but Balance Sheet Strain Remains

Anaprazole prescriptions are widening and quarterly operating losses narrowed to KRW 281 million in Q3 2026, but the 2025 swing to losses and a 127.7% debt ratio have yet to ease.

  1. 1

    Anaprazole, a domestic No. 38 new drug, was launched in October 2025 and has passed pharmacy committee reviews at more than 60 hospitals with 300 or more beds. The company said on November 16, 2026 that it placed an additional order of about 113,000 vials.

  2. 2

    Q3 2026 sales rose to KRW 15.6 billion, up 131.5% year on year, and the operating loss narrowed to KRW 281 million from KRW 10.2 billion in Q3 2025.

  3. 3

    Full-year 2025 sales fell 32.3% to KRW 59.3 billion, and the company swung to an operating loss of KRW 19.2 billion. The net loss attributable to controlling shareholders was KRW 32.4 billion.

  4. 4

    The non-opioid candidate VVZ-2471 began first patient dosing in a U.S. Phase 1b study, announced November 10, 2026, while the Korean Phase 2 trial in postherpetic neuralgia is in data analysis. The company said it is advancing global licensing talks.

  5. 5

    At the end of 2025, total equity was KRW 72.7 billion and total liabilities were KRW 92.8 billion, a debt ratio of 127.7%. Operating cash flow in 2025 was -KRW 6.87 billion.

02

Business structure

Vivozon Pharmaceutical is a drugmaker that manufactures and sells prescription medicines, and its core product is Anaprazole (generic name opiranserin), an injectable non-opioid analgesic.

Anaprazole is a domestic No. 38 new drug that controls pain by inhibiting glycine transporter 2 (GlyT2) and antagonizing serotonin receptor 2A (5-HT2A) (Financial News, November 16, 2026).

Its indication is moderate-to-severe pain management after surgery, positioned as an option that can reduce the risks of addiction and respiratory depression linked to opioid analgesics (Korea Financial News, November 16, 2026).

Since its October 2025 launch, more than 60 hospitals with 300 or more beds have passed pharmacy committee review, and prescription codes have been registered at major tertiary hospitals and national university hospitals including Samsung Seoul Hospital and Sinchon Severance Hospital (ZDNet Korea, November 16, 2026).

The company is also widening its customer base to local clinics in orthopedics, neurosurgery, and anesthesiology and pain medicine. Production is handled by the Chinese partner Sichuan Huiyu Pharmaceutical, so supply depends on an outside manufacturing partner.

The company signed an export deal in Hainan Province, China for Larafan tablets, a colonoscopy bowel-prep product, and targets first shipments in Q1 2027 (Korea Financial News, November 16, 2026).

An affiliate is developing VVZ-2471, an oral non-opioid analgesic candidate that acts on serotonin receptor 2A and metabotropic glutamate receptor 5 at the same time (Asia Economy, November 10, 2026). In Korea, a Phase 2 trial in postherpetic neuralgia has been completed and data are under analysis, while a U.S.

Phase 1b study in opioid use disorder started (Edaily, November 10, 2026). The pipeline also includes VVZ-3416 for degenerative neurological disease and the schizophrenia candidate N3, which is approaching preclinical study (Daily Hankook, December 26, 2025). Product-level sales mix comes from the segment information in the periodic reports.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.8B-₩10.2B−151.0%
2025Q4₩16.2B-₩3.7B−23.0%
2026Q1₩14.1B-₩3B−21.4%
2026Q2₩13.3B-₩1.9B−14.6%
2026Q3₩15.6B-₩300M−1.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩59.1B-₩18.5B-₩38.5B−31.4%−36.3%76.8%
2023₩71.3B₩2.6B-₩3.4B3.6%−3.2%66.9%
2024₩87.6B₩2.9B-₩10B3.3%−9.4%73.3%
2025₩59.3B-₩19.2B-₩32.4B−32.3%−44.6%127.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a disclosed basis, annual sales rose from KRW 59.1 billion in 2022 to KRW 71.3 billion in 2023 (up 20.7% year on year) and KRW 87.6 billion in 2024 (up 22.8%), then fell to KRW 59.3 billion in 2025 (down 32.3%). 2024 was the largest year in the 2022–2025 period and 2022 the smallest.

Operating performance moved from an operating loss of KRW 18.5 billion in 2022 to an operating profit of KRW 2.59 billion in 2023, a swing to profit, and rose to KRW 2.85 billion in 2024 (up 10.4%). In 2025 the company swung back to an operating loss of KRW 19.2 billion.

Operating margins were -31.4% in 2022, 3.6% in 2023, 3.3% in 2024, and -32.3% in 2025. In 2023 and 2024 sales growth coincided with a positive operating margin, while in 2025 the sales decline came with a sharp margin reversal.

The net loss attributable to controlling shareholders was KRW 38.5 billion in 2022, narrowed to KRW 3.36 billion in 2023, widened to KRW 9.98 billion in 2024, and reached KRW 32.4 billion in 2025.

The net loss including non-controlling interests was KRW 39.2 billion in 2022, KRW 3.36 billion in 2023, KRW 9.98 billion in 2024, and KRW 32.4 billion in 2025, and the company has reported losses in each of the four years from 2022 to 2025.

The debt ratio, defined as total liabilities divided by total equity, was 76.8% in 2022, 66.9% in 2023, 73.3% in 2024, and 127.7% in 2025. Operating cash flow went from -KRW 3.32 billion in 2022 to KRW 2.99 billion in 2023 and KRW 5.73 billion in 2024, then turned to -KRW 6.87 billion in 2025.

On a quarterly basis, sales rose from KRW 6.76 billion in Q3 2025 with an operating loss of KRW 10.2 billion to KRW 16.2 billion in Q4 2025 (up 139.7% quarter on quarter), and the operating loss narrowed to KRW 3.73 billion.

Sales then declined to KRW 14.1 billion in Q1 2026 (down 12.9%) and KRW 13.3 billion in Q2 2026 (down 5.8%), while operating losses narrowed to KRW 3.02 billion and KRW 1.94 billion. Q3 2026 sales were KRW 15.6 billion (up 17.8% quarter on quarter and up 131.5% year on year), and the operating loss was KRW 281 million.

The net loss attributable to controlling shareholders narrowed from KRW 11.6 billion in Q3 2025 and KRW 12.8 billion in Q4 2025 to KRW 806 million in Q3 2026, and the four quarters from Q4 2025 to Q3 2026 total KRW 22 billion.

The company has posted an operating loss and a net loss attributable to controlling shareholders for five consecutive quarters from Q3 2025 to Q3 2026.

The quarterly sales recovery overlaps with the timing of the Anaprazole launch, and the sales breakdown by quarter comes from the segment information in the periodic reports.

05

Industry analysis

The front market for Vivozon Pharmaceutical is pain treatment after surgery for moderate-to-severe cases, where the side-effect burden of opioid analgesics, including addiction and respiratory depression, creates demand for alternatives.

Anaprazole is classified as a non-opioid therapy that works differently from opioid analgesics (Financial News, November 16, 2026). The company presents Anaprazole as a first-in-class innovative drug, and reports say the MFDS approval came in December 2024 (The Value News, December 2025).

At this stage of the cycle, the drug is in an early commercial phase, widening prescribing hospitals while order volumes rise.

The limits of existing treatments are also cited as a demand factor: the company said gabapentinoid-class drugs used in postherpetic neuralgia offer limited effects and central nervous system side effects such as drowsiness and dizziness (Newsis, May 12, 2026).

On the industry front, the chairman said on December 26, 2025 that four of the global top 10 drugmakers and a Japanese drugmaker invited the company to the JPM Healthcare Conference (Daily Hankook, December 26, 2025).

He also said that non-opioid analgesics and central nervous system drugs had not been major investment targets over the past decade, a view that reflects the company's own perspective on the sector. Competitively, Anaprazole aims to replace opioid analgesics within the post-surgical pain indication. The company's results are best read as depending on how fast Anaprazole sales expand.

06

Outlook

The most specific target the company has stated is to begin first exports of Larafan tablets to Hainan Province, China in Q1 2027 (Korea Financial News, November 16, 2026).

Anaprazole continues to expand prescriptions at large hospitals, and the number of institutions passing pharmacy committee review serves as a gauge of that expansion. The additional order of about 113,000 vials announced on November 16, 2026 is a response to rising prescriptions (Financial News, November 16, 2026).

Order volume is an indirect gauge of sales trends, and whether orders translate into quarterly revenue will show in later quarterly results.

The company said it plans to launch a small-pack formulation of Anaprazole and advance clinical work on an external-use product this year (Korea Financial News, November 11, 2026).

For VVZ-2471, data analysis is under way for the Korean Phase 2 trial in postherpetic neuralgia, and the company said it will use topline results to firm up follow-on development and global licensing talks (Newsis, May 12, 2026). The U.S.

Phase 1b study focuses mainly on safety and tolerability under repeated dosing, and results will shape the design of later trials in opioid use disorder (Financial News, November 10, 2026).

Patent rights now cover eight countries and regions after the Korean decision and an Israeli registration (Financial News, November 10, 2026).

Licensing talks were at the discussion stage around the end of 2025 at the BIO Europe and JPM events, and the timing of any signed agreement will become visible only through company announcements. The next checkpoint is the 2026 annual report, where full-year sales and operating margin will show.

07

Valuation

PER
—
PBR
1.9×
ROE
-24.1%
EPS
-₩417
BPS
₩1,638
Dividend per share
₩0

The current share price is above the book value of total equity, so the price-to-book ratio sits above 1x, meaning the stock carries a premium over net assets. That premium can be read as reflecting expectations for the pipeline and Anaprazole sales.

The P/E ratio cannot be calculated because the last four quarters were net losses, so comparisons rely on asset-based measures rather than earnings-based multiples. The dividend yield is effectively nil, so the company does not offer a dividend-based return.

Looking back, the company had operating profit in 2023 and 2024 before swinging to a loss in 2025, and the size of recent quarterly losses has been shrinking. The debt ratio rose from 76.8% in 2022 to 127.7% in 2025, meaning the debt burden relative to equity has grown.

How far market value exceeds book equity depends largely on Anaprazole sales scale and clinical results. Comparisons with listed peers should use the same date to be accurate.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Wider Anaprazole prescribing base

Since its October 2025 launch, more than 60 hospitals with 300 or more beds have passed pharmacy committee review, and national university hospitals have registered prescription codes. Whether the wider prescribing base converts into higher sales volume is the test for this factor.

Quarterly operating losses narrowing

The operating loss narrowed from KRW 10.2 billion in Q3 2025 to KRW 281 million in Q3 2026, with the loss shrinking in each quarter in between. Q3 2026 sales were KRW 15.6 billion, up 131.5% year on year. This trend overlaps with the period after the Anaprazole launch, when sales scale grew.

VVZ-2471 clinical progress

The Korean Phase 2 trial in postherpetic neuralgia has finished dosing and is in data analysis. In company-released data, 32% of patients in the high-dose group saw pain fall by 40% or more, more than double the 15% in the placebo group. These are company-disclosed figures, and the assessment could change once topline results are released.

09

Bear factors

Accumulated losses and debt burden

On a disclosed basis, the company has posted losses in each of the four years from 2022 to 2025, with a net loss attributable to controlling shareholders of KRW 32.4 billion in 2025. At the end of 2025, total liabilities of KRW 92.8 billion exceeded total equity of KRW 72.7 billion. The debt ratio rose to 127.7% from 76.8% in 2022.

Sales decline and weak cash flow

Sales fell 32.3% to KRW 59.3 billion in 2025, and operating cash flow was -KRW 6.87 billion. Despite the quarterly sales increase after the Anaprazole launch, sales declined quarter on quarter in Q1 and Q2 2026. Whether quarterly sales settle on a steady growth path will depend on the quarters ahead.

Uncertain licensing outcomes

The chairman acknowledged a view that talks with global drugmakers have grown but have not yet led to licensing deals (Daily Hankook, December 26, 2025). Among the pipeline, VVZ-3416 and N3 remain at the preclinical stage. The U.S. Phase 1b study is designed mainly to assess safety, so it does not offer efficacy evidence.

10

Risk factors

Clinical outcome risk

Topline results from the Korean Phase 2 trial of VVZ-2471 have not yet been released. The U.S. Phase 1b study targets safety and tolerability. If clinical results fall short of expectations, licensing talks and plans to expand indications could be delayed together. The efficacy figures the company has released center on the high-dose group.

Financing and balance sheet risk

At the end of 2025, total liabilities were KRW 92.8 billion against total equity of KRW 72.7 billion, a debt ratio of 127.7%. If sales recovery is slow, the need for additional funding could grow, and the chosen financing method could affect the value of existing shareholders' stakes.

Supply and prescribing structure risk

Anaprazole is manufactured by the Chinese partner Sichuan Huiyu Pharmaceutical, so production disruptions at the partner or changes in local regulation could affect supply volumes. Domestic prescribing is moving from large hospitals to local clinics, so shifts in prescribing patterns are another variable.

11

What to watch next

  1. Date not set (after November 2026)

    Topline results of the Korean Phase 2 trial of VVZ-2471 in postherpetic neuralgia. The company plans to announce key endpoints after data analysis, and the outcome will shape licensing talks and the direction of indication expansion.

  2. By end-2026

    Whether the small-pack Anaprazole formulation launches and the external-use clinical work advances. This is the point to check whether formulation expansion aligns with wider prescribing.

  3. Q1 2027

    Whether first exports of Larafan tablets to Hainan Province, China begin. If shipments start, the company gains a revenue source beyond domestic Anaprazole sales.

  4. End-March 2027 (annual report filing deadline)

    The 2026 annual report, which brings full-year 2026 sales, operating margin, debt ratio, and operating cash flow into the disclosed record.

12

Overall view

Vivozon Pharmaceutical is in a phase where prescription growth for Anaprazole and a narrowing quarterly operating loss appear at the same time. Q3 2026 sales were KRW 15.6 billion, up 131.5% year on year, and the operating loss narrowed to KRW 281 million.

On a full-year basis, however, 2025 showed sales of KRW 59.3 billion (down 32.3%), an operating loss of KRW 19.2 billion, and a net loss attributable to controlling shareholders of KRW 32.4 billion.

On the balance sheet, the debt ratio was 127.7% at the end of 2025 and operating cash flow was -KRW 6.87 billion, so the debt burden eases only if the sales recovery continues. In the pipeline, the key variables are the topline results of the Korean Phase 2 trial of VVZ-2471, the progress of the U.S.

Phase 1b study, and global licensing talks. Strengths include wider prescribing and a shrinking quarterly loss, while weaknesses include accumulated losses, debt, and uncertainty around clinical results and licensing.

The next checkpoints are full-year operating margin in the 2026 annual report and whether Larafan exports to China begin in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. jobkorea.co.kr
  2. fntimes.com
  3. fnnews.com
  4. zdnet.co.kr
  5. view.asiae.co.kr
  6. eduinfom.com
  7. fnnews.com
  8. insight.goover.ai
  9. thevaluenews.co.kr
  10. fntimes.com
  11. thebionews.net
  12. edaily.co.kr
  13. m.news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis